NCT03715127View on ClinicalTrials.gov

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

October 12, 2021

Study Completion Date

April 12, 2022

Conditions
Depressive Disorder, Major
Interventions
DRUG

Psilocybine oral capsule

single dose of psilocybin (0.215mg / kg body weight)

DRUG

Placebo oral capsule

single dose of placebo (100% mannitol)

Trial Locations (1)

8032

Psychiatrische Universitätsklinik Zürich, Zurich

All Listed Sponsors
collaborator

Schweizerischer Nationalfonds

OTHER

lead

University of Zurich

OTHER

NCT03715127 - Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept | Biotech Hunter | Biotech Hunter